Adma Biologics (ADMA) Net Margin (2016 - 2025)
Historic Net Margin for Adma Biologics (ADMA) over the last 13 years, with Q3 2025 value amounting to 27.14%.
- Adma Biologics' Net Margin fell 28200.0% to 27.14% in Q3 2025 from the same period last year, while for Sep 2025 it was 42.87%, marking a year-over-year increase of 250700.0%. This contributed to the annual value of 46.35% for FY2024, which is 572900.0% up from last year.
- Adma Biologics' Net Margin amounted to 27.14% in Q3 2025, which was down 28200.0% from 28.05% recorded in Q2 2025.
- In the past 5 years, Adma Biologics' Net Margin registered a high of 95.19% during Q4 2024, and its lowest value of 114.26% during Q1 2021.
- Moreover, its 5-year median value for Net Margin was 11.93% (2023), whereas its average is 13.94%.
- In the last 5 years, Adma Biologics' Net Margin surged by 1534600bps in 2021 and then tumbled by -28200bps in 2025.
- Quarter analysis of 5 years shows Adma Biologics' Net Margin stood at 30.01% in 2021, then increased by 21bps to 23.59% in 2022, then decreased by -1bps to 23.88% in 2023, then skyrocketed by 499bps to 95.19% in 2024, then plummeted by -71bps to 27.14% in 2025.
- Its last three reported values are 27.14% in Q3 2025, 28.05% for Q2 2025, and 23.44% during Q1 2025.